Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $150.00 | 1 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Galderma Laboratories, L.P. | $150.00 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $150.00 | 1 | Galderma Laboratories, L.P. ($150.00) |
All Payment Transactions
1 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/10/2020 | Galderma Laboratories, L.P. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $150.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 2,221 | 4,225 | $614,980 | $216,776 |
| 2022 | 19 | 2,238 | 4,315 | $634,944 | $216,883 |
| 2021 | 19 | 2,009 | 3,879 | $548,803 | $195,599 |
| 2020 | 17 | 1,629 | 2,887 | $429,718 | $151,566 |
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 431 | 658 | $137,051 | $50,401 | 36.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 264 | 349 | $84,587 | $30,197 | 35.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 371 | 555 | $88,163 | $24,737 | 28.1% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 77 | 104 | $44,220 | $15,756 | 35.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 121 | 147 | $39,790 | $14,658 | 36.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 100 | 129 | $37,882 | $13,555 | 35.8% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 125 | 236 | $28,278 | $11,643 | 41.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 121 | 121 | $31,744 | $11,303 | 35.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 273 | 1,528 | $23,806 | $9,541 | 40.1% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 25 | 30 | $21,769 | $8,602 | 39.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 128 | 157 | $20,658 | $7,588 | 36.7% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 44 | 45 | $13,541 | $5,246 | 38.7% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 16 | 20 | $8,085 | $3,231 | 40.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $8,857 | $3,013 | 34.0% |
| 17263 | Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | Office | 2023 | 14 | 15 | $6,866 | $2,373 | 34.6% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 15 | 16 | $9,306 | $1,918 | 20.6% |
| 69100 | Biopsy of ear | Office | 2023 | 17 | 17 | $3,913 | $1,135 | 29.0% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 19 | 26 | $3,531 | $950.98 | 26.9% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 17 | 17 | $2,863 | $900.90 | 31.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 20 | 32 | $68.87 | $27.71 | 40.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 427 | 653 | $139,735 | $49,352 | 35.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 293 | 359 | $90,048 | $31,178 | 34.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 377 | 564 | $92,462 | $25,478 | 27.6% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2022 | 63 | 95 | $41,316 | $14,293 | 34.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 162 | 162 | $43,638 | $13,993 | 32.1% |
About Dr. Mark Halsey, MD
Dr. Mark Halsey, MD is a Pediatric Dermatology healthcare provider based in Sag Harbor, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2011. The National Provider Identifier (NPI) number assigned to this provider is 1790070480.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Halsey, MD has received a total of $150.00 in payments from pharmaceutical and medical device companies, with $150.00 received in 2020. These payments were reported across 1 transactions from 1 company. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($150.00).
As a Medicare-enrolled provider, Halsey has provided services to 8,097 Medicare beneficiaries, totaling 15,306 services with total Medicare billing of $780,824. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Practice Information
- Specialty Pediatric Dermatology
- Other Specialties Procedural Dermatology, Dermatology
- Location Sag Harbor, NY
- Active Since 06/10/2011
- Last Updated 08/05/2025
- Taxonomy Code 207NP0225X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1790070480
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.